Revised reference broth microdilution method for testing telavancin: Effect on MIC results and correlation with other testing methodologies

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 9, 2014, Pages 5547-5551

  Farrell, David J ^a   Mendes, Rodrigo E ^a   Rhomberg, Paul R ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALBAVANCIN; DIMETHYL SULFOXIDE; ORITAVANCIN; PLASTIC; POLYSORBATE 80; TELAVANCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; POLYSORBATE;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; BROTH DILUTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG BINDING; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; CHEMISTRY; DRUG EFFECTS; ENTEROCOCCUS; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; PROCEDURES; STREPTOCOCCUS;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; DIMETHYL SULFOXIDE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS; MICROBIAL SENSITIVITY TESTS; POLYSORBATES; STAPHYLOCOCCUS; STREPTOCOCCUS;

EID: 84906075958     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03172-14     Document Type: Article

References (17)

1. Mendes RE, Sader HS, Farrell DJ, Jones RN. 2012. Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA hospitals (2007-2009). Diagn. Microbiol. Infect. Dis. 72:113-117. http://dx.doi.org/10.1016/j.diagmicrobio.2011.09.023.
2. Farrell DJ, Krause KM, Benton BM. 2011. In vitro activity of telavancin and comparator antimicrobial agents against a panel of genetically defined staphylococci. Diagn. Microbiol. Infect. Dis. 69:275-279. http://dx.doi.org/10. 1016/j.diagmicrobio.2010.09.017.
3. Theravance, Inc. 2014. Vibativ, package insert. Theravance, Inc., South San Francisco, CA. http://www.vibativ.com. Accessed 25 April 2014.
4. Rennie RP, Koeth L, Jones RN, Fritsche TR, Knapp CC, Killian SB, Goldstein BP. 2007. Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent. J. Clin. Microbiol. 45:3151-3154. http://dx.doi.org/10.1128/JCM.02411-06. (Pubitemid 47585633)
5. Arhin FF, Sarmiento I, Belley A, McKay GA, Draghi DC, Grover P, Sahm DF, Parr TR, Jr, Moeck G. 2008. Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing. Antimicrob. Agents Chemother. 52:1597-1603. http://dx.doi.org/10.1128/AAC.01513-07. (Pubitemid 351614648)
6. Anderegg TR, Biedenbach DJ, Jones RN. 2003. Initial quality control evaluations for susceptibility testing of dalbavancin (BI397), an investigational glycopeptide with potent Gram-positive activity. J. Clin. Microbiol. 41:2795-2796. http://dx.doi.org/10.1128/JCM.41.6.2795-2796.2003. (Pubitemid 36712523)
7. Arhin FF, Tomfohrde K, Draghi DC, Aranza M, Parr TR, Jr, Sahm DF, Moeck G. 2008. Newly defined in vitro quality control ranges for oritavancin broth microdilution testing and impact of variation in testing parameters. Diagn. Microbiol. Infect. Dis. 62:92-95. http://dx.doi.org/10.1016/j.diagmicrobio.2008. 05.009.
8. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing: 24th informational supplement M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Ross JE, Mendes RE, Jones RN. 11 June 2014. Quality control MIC ranges used for telavancin with application of a revised CLSI reference broth microdilution method. J. Clin. Microbiol. http://dx.doi.org/10.1128/JCM.01210- 14.
10. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing: 23rd informational supplement M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M07-A9, 8th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
12. U.S. Food and Drug Administration. 2009. Guidance for industry and FDA. Class II special controls guidance document: antimicrobial susceptibility test (AST) systems. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ GuidanceDocuments/ucm080564.htm. Accessed 12 February 2014.
13. Mendes RE, Sader HS, Farrell DJ, Jones RN. 2011. Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010). Diagn. Microbiol. Infect. Dis. 71:93-97. http://dx.doi.org/10.1016/j. diagmicrobio.2011.05.012.
14. Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF. 2008. Comparative surveillance study of telavancin activity against recently collected Gram-positive clinical isolates from across the United States. Antimicrob. Agents Chemother. 52:2383-2388. http://dx.doi.org/10.1128/AAC.01641-07. (Pubitemid 351915666)
15. Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF. 2008. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. J. Antimicrob. Chemother. 62:116-121. http://dx.doi.org/10.1093/jac/dkn124. (Pubitemid 351865882)
16. Jones RN, Flamm RK, Sader HS. 2013. Surveillance of dalbavancin potency and spectrum in the United States (2012). Diagn. Microbiol. Infect. Dis. 76:122-123. http://dx.doi.org/10.1016/j.diagmicrobio.2013.01.003.
17. Mendes RE, Sader HS, Flamm RK, Farrell DJ, Jones RN. 18 February 2014. Oritavancin activity against Staphylococcus aureus causing invasive infections in USA and European hospitals. A five-year international surveillance program. Antimicrob. Agents Chemother. http://dx.doi.org/10.1128/AAC.02482-13.